- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02020954
Prospective Becker-Heart-Study (Becker-HS)
Prospective Cohort Study of Patients With Mutations in the Dystrophin Gene (X Linked Dilated Cardiomyopathy and Becker Muscular Dystrophy)
Study Overview
Status
Intervention / Treatment
Detailed Description
A cohort of 100 patients with mutations in the dystrophin gene associated with Becker muscular dystrophy and/or dilated cardiomyopathy will be included (patients with Duchenne muscular dystrophy are excluded).
Patients with undergo at baseline the following workups: electrocardiogram, echocardiography, cardiac MRI, sera biomarkers measurement.
At 3 years and 5 years, patients will be investigated according to the same protocol and occurrence of cardiac adverse events in the meanwhile will be recorded.
Statistical analysis will assess correlations between cardiac phenotype and DMD mutations and prognostic value of cardiac investigations.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Ile de France
-
Paris, Ile de France, France, 75013
- Recruiting
- Institut de Myologie
-
Contact:
- Nawal Berber, PhD
- Email: n.benammar@institut-myologie.org
-
Principal Investigator:
- Karim Wahbi, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- mutation in the DMD gene
- Becker muscular dystrophy and/or dilated cardiomyopathy
- age>18 years
- affiliation to the French medical insurance
Exclusion Criteria:
- Duchenne muscular dystrophy
- Any other chronic disease that may be associated with heart disease
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Dystrophinopathy
Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Left ventricular ejection fraction
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Composite endpoint: hospitalisation for heart failure, death due to heart failure
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karim Wahbi, MD, PhD, Institut de Myologie, Cochin Hospital, Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Becker-Heart-Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.